Curis (NASDAQ:CRIS) Posts Earnings Results, Beats Estimates By $2.93 EPS

Curis (NASDAQ:CRIS) announced its earnings results on Friday. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93, FiscalAI reports.

Curis Trading Down 3.7%

Curis stock opened at $1.80 on Friday. The firm has a market capitalization of $3.76 million, a price-to-earnings ratio of -0.13 and a beta of 3.13. Curis has a 1-year low of $1.54 and a 1-year high of $39.00. The firm has a 50 day simple moving average of $5.84 and a 200 day simple moving average of $11.74.

Wall Street Analysts Forecast Growth

CRIS has been the subject of several recent research reports. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded Curis to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $43.00 price objective (up from $17.00) on shares of Curis in a report on Friday, July 24th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $43.00.

Institutional Trading of Curis

A number of large investors have recently modified their holdings of the business. Armistice Capital LLC lifted its stake in Curis by 8.7% during the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 78,265 shares during the last quarter. Maverick Capital Ltd. grew its holdings in shares of Curis by 7.8% during the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after buying an additional 230,659 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 27,343 shares during the period. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.